Yasir Al-Wakeel

Yasir B. Al-Wakeel joined Neon Therapeutics in 2017 as the company’s chief financial officer. Prior to Neon, Yasir served as chief financial officer and head of corporate development of Merrimack Pharmaceuticals, where he spearheaded the strategic sale of Onivyde® and a generic version of Doxil® to Ipsen S.A. for up to $1.025 billion.

Yasir previously served in various capacities at Credit Suisse, an investment banking firm, including, most recently, the role of director of health care investment banking focused on biotechnology. Prior to that role, Yasir was an equity research analyst for Credit Suisse covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Yasir was a practicing physician, holding both clinical and academic medical posts.

Yasir holds a B.M., B.Ch. (Doctor of Medicine) from Oxford University, and an M.A. in theology from Cambridge University.